標題
返回
確定
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
Minghui Pharmaceutical
#
Minghui Pharmaceutical
About 2 search results
Sort by Date
Business
PR Newswire
Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
SHANGHAI and HANGZHOU, China and WILMINGTON, Del.
PR Newswire
2026-06-16 09:00
MHB018A
Minghui Pharmaceutical
Thyroid Eye Disease
Business
PR Newswire
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China
PR Newswire
2026-06-01 12:00
MHB088C
mCRPC
Minghui Pharmaceutical